Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) versus abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor-positive/human epidermal growth factor receptor–negative (HR+/HER2−) advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC) Meeting Abstract
| Authors: | Rugo, H. S.; O'Shaughnessy, J.; Jhaveri, K. L.; Tolaney, S. M.; Cardoso, F.; Bardia, A.; Maheshwari, V. K.; Tripathi, S.; Pathak, P.; Haftchenary, S.; Fasching, P. A. |
| Abstract Title: | Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) versus abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor-positive/human epidermal growth factor receptor–negative (HR+/HER2−) advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC) |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680300072 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.1015 |
| Notes: | Meeting Abstract: 1015 -- Meeting also held virtually -- Source: Wos |
